Teva Pharmaceutical Industries (TEVA) U.S. All Stars Conference summary

Strategic transformation and growth

• Transitioned from a pure generics company to a biopharma with a focus on innovation and portfolio diversification.

• Four strategic pillars: growth engine delivery, innovation, generics powerhouse, and business focus.

• Innovative business grew 40% in Q2, with all marketed products growing at double digits.

• Maintained OpEx as a percentage of revenue while reallocating capital to support launches and R&D.

• Execution of detailed strategy has built credibility and momentum for sustained growth.

Product pipeline and launches

• Robust pipeline includes duvakitug (anti-TL1A), anti-IL-15, olanzapine LAI, ecopipam, and DARI, with annual launches expected for the next five years.

• Each major asset is expected to drive growth, with a clear path to top and bottom line expansion.

• Olanzapine LAI targets a $1.5–$2 billion franchise, with potential for more depending on market dynamics.

• Ecopipam for Tourette’s is positioned as a transformative therapy in an underserved market.

• TL1A antibody is claimed to be best-in-class, with strong engineering and safety profile.

Financial performance and targets

• Gross margin improved from 48% to 55%, driven by innovative portfolio and disciplined OpEx.

• Targeting 30% operating margin by 2027, supported by portfolio mix and $700 million in cost savings.

• Innovative sales grew from $1.2 billion in 2022 to $1 billion per quarter, with further growth expected.

• Generics business stabilized and returned to growth, with biosimilars now a significant part of the portfolio.

• Capital allocation prioritizes growth drivers, pipeline investment, and disciplined BD, with limited focus on dividends or buybacks.